PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer

被引:3
|
作者
Wang, Jiaxi [1 ,2 ,3 ,4 ]
Peng, Yuanyuan [1 ]
Guo, Hejia [5 ]
Li, Cuiping [2 ,3 ,4 ,6 ]
机构
[1] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Periodontal & Oral Med, Nanning, Peoples R China
[2] Guangxi Key Lab Oral & Maxillofacial Rehabil & Re, Nanning, Peoples R China
[3] Guangxi Key Lab Oral & Maxillofacial Surg Dis Tre, Nanning, Peoples R China
[4] Guangxi Med Univ, Coll Stomatol, Guangxi Hlth Commiss Key Lab Prevent & Treatment, Guangxi Clin Res Ctr Craniofacial Deform, Nanning, Peoples R China
[5] Guangxi Med Univ, Coll & Hosp Stomatol, Dept Oral & Maxillofacial Surg, Nanning, Peoples R China
[6] Guangxi Med Univ, Coll Stomatol, Med Sci Res Ctr, Nanning, Peoples R China
关键词
cancer; polymorphism; PAI-1; meta-analysis; PLASMINOGEN-ACTIVATOR INHIBITOR-1; 4G/5G POLYMORPHISM; GENE POLYMORPHISMS; SUSCEPTIBILITY; EXPRESSION; SYSTEM; PROBABILITY; ANTIGEN; FALSE; UPA;
D O I
10.1177/15330338211037813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The plasminogen activator inhibitor-1 (PAI-1) was found in many types of tumor cells, which involved in tumorigenesis. Some studies investigated the associations between PAI-1 polymorphisms and various cancers, but the results were inconsistent. So this study did a meta-analysis to assess the strength of relationship between PAI-1 and cancer. Methods: Articles that meet the requirements were searched from PubMed, EMBASE, MEDLINE, Scopus, CNKI, Wanfang and SinoMed electronic databases before June 17th 2021. Stata version 11.2 was performed to merge the odds ratios (ORs) values and calculate 95% confidence intervals (CIs). Stratified analyses were assessed on the basis of types of cancer, ethnicity and source of the control group. Heterogeneity and sensitivity analysis were tested, and publication bias was also estimated. A meta-regression analysis was applied to explore sources of heterogeneity. The false-positive report probabilities (FPRP) and the Bayesian False Discovery Probability (BFDP) test were used to assess the credibility of statistically significant associations. Results: Ultimately, in this study, 33 eligible reports were included with 9550 cases and 10431 controls for the rs1799889 polymorphism, 5 reports with 2705 cases and 3168 controls for the rs2227631 polymorphism, and 4 reports with 2799 cases and 4011 controls for the rs2227667 polymorphism. The ORs and 95% CIs showed a statistically significant relationship between rs1799889 4G>5G polymorphism and cancer risk, especially in feminine cancer. The term refers to cancers that occur in the female reproductive system, such as ovarian, breast, endometrial and cervical cancer. Moreover, there was no association observed for the PAI-1 promoter A>G polymorphism (rs2227631 and rs2227667). In further subgroup analyses of 4G>5G polymorphism (rs1799889), an increased susceptibility to cancer was observed in Caucasians group and some types of cancer groups. Conclusions: This article comes to a conclusion that the rs1799889 polymorphism might help to increase the risk of cancer; moreover, the susceptibility to feminine cancer is more evident.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Regulation of PAI-1 expression by genetic polymorphisms - Impact on atherogenesis
    Nordt, TK
    Lohrmann, J
    Bode, C
    THROMBOSIS RESEARCH, 2001, 103 : S1 - S5
  • [32] The value of uPA and PAI-1 levels in triple negative breast cancer
    Sobocan, M.
    Ledinek, Z.
    Crnobrnja, B.
    Sikosek, N. Cas
    Dovnik, N. Fokter
    Kavalar, R.
    Knez, J.
    Takac, I.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S73 - S74
  • [33] Quantitative protein network monitoring for uPA and PAI-1 in breast cancer
    Malinowsky, K.
    Boellner, C.
    Berg, D.
    Walch, A.
    Schuster, T.
    Schmitt, M.
    Becker, K. -F.
    VIRCHOWS ARCHIV, 2010, 457 (02) : 172 - 172
  • [34] PAI-1 is independant prognostic factor in the elderly breast cancer patients
    Pajk, B
    Borstnar, S
    Vrhovec, I
    Cufer, T
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S111 - S111
  • [35] Cathepsin D and PAI-1 expression in human head and neck cancer
    Zeillinger, R
    Eder, S
    Schneeberger, C
    Ullrich, R
    Speiser, P
    Swoboda, H
    ANTICANCER RESEARCH, 1996, 16 (01) : 449 - 453
  • [36] uPA and PAI-1 in Rectal Cancer - Relationship to Radiotherapy and Clinical Outcome
    Angenete, Eva
    Langenskiold, Marcus
    Palmgren, Ingrid
    Falk, Peter
    Oresland, Tom
    Ivarsson, Marie-Louise
    JOURNAL OF SURGICAL RESEARCH, 2009, 153 (01) : 46 - 53
  • [37] Differential Prognostic Impact of uPA and PAI-1 in Colon and Rectal Cancer
    Langenskiold, Marcus
    Holmdahl, Lena
    Angenete, Eva
    Falk, Peter
    Nordgren, Svante
    Ivarsson, Marie-Louise
    TUMOR BIOLOGY, 2009, 30 (04) : 210 - 220
  • [38] Proapoptotic effects of PAI-1 protein on lung and prostate cancer cells
    Rozy, Adriana
    Kedzior, Marta
    Chorostowska-Wynimko, Joanna
    Szpechcinski, Adam
    Skrzypczak-Jankun, Ewa
    Jankun, Jerzy
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [39] uPA and PAI-1 in primary breast cancer:: from bench to bedside
    Harbeck, Nadia
    Jaenicke, Fritz
    Schmitt, Manfred
    Thomssen, Christoph
    EJC SUPPLEMENTS, 2004, 2 (03): : 26 - 27
  • [40] ACE and PAI-1 gene polymorphisms in renal transplant recipients
    Cristallo, A. F.
    Fiordoro, S.
    Rosetta, P.
    Paolucci, I.
    Santori, G.
    Fontana, I.
    Tagliamacco, A.
    Bertani, G.
    Nocera, A.
    Valente, U.
    Barocci, S.
    TISSUE ANTIGENS, 2011, 77 (05): : 445 - 445